Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment Policyglobalhealth Part D EUA Antivirals Coverage Update…
    Ask Trek AI about this page
    ModifiedglobalhealthPolicy N/A

    Introduction of Prescription Oral Antivirals for COVID-19 to the Commercial Market

    Customize your policy alerts

    Sign up for all globalhealth policy alerts

    Know when globalhealth releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Guidance for Medicare Part D sponsors on formulary inclusion, claims processing, and reporting for commercial and USG-distributed oral antivirals (Paxlovid and Lagevrio) as they transition to the commercial market; affects Part D sponsors, pharmacies, and Medicare beneficiaries.

    Policy Summary
    Payerglobalhealth
    PolicyIntroduction of Prescription Oral Antivirals for COVID-19 to the Commercial Market
    Policy CodePolicy N/A
    Change TypeModified guidance expanding prior memorandum for commercial transition
    Effective DateFeb 20, 2024
    Next Review DateN/A
    Key ActionPart D sponsors must process expedited coverage determinations when delay could jeopardize beneficiary health.
    SourceLink
    POLICY UPDATE CHANGES

    Guidance expanding prior November 4, 2022 memorandum to address transition of oral antivirals to the commercial market and dual supplies (USG-distributed and commercial).

    Commercial Paxlovid is available through a patient assistance program (USG PAP) allowing $0 cost sharing for beneficiaries through December 31, 2024, including a Part D plan-facilitated pathway and a standalone Pfizer-operated pathway.

    CMS will reject PDEs for EUA-labeled Paxlovid with dates of service after March 8, 2024.

    Nov 1, 2023commercial market entry
    Dec 31, 2024

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Part D EUA coverage end
    Mar 8, 2024PDE rejection date (EUA Paxlovid)
    through Dec 31, 2024Pfizer USG PAP availability
    0standalone PAP cost sharing

    Coverage and Beneficiary Pathways

    Part D coverage and operational criteria for oral antivirals

    Covered when ALL of the following are met:

    EUA oral antivirals that meet the statutory definition of a Part D drug must be covered by Part D plans either on formulary or via the formulary exception process consistent with 42 CFR § 423.578(b).
    CMS encourages adding at least one oral antiviral for COVID-19 to CY2024 formularies on a preferred or $0 cost-sharing tier where available; Part D sponsors may apply utilization management (UM) edits but should favor soft reject edits resolvable at point-of-sale and avoid edits that unduly delay initiation of therapy.
    Operational rule for Part D sponsors that contract with Pfizer to facilitate the USG patient assistance program (PAP): commercial Paxlovid must be added to the formulary without prior authorization or step therapy; quantity limits for a single full course are permitted; in-network and qualifying out-of-network claims must be processed at $0 cost sharing for dates Nov 1, 2023–Dec 31, 2024; sponsors must invoice Pfizer for rebates and report related rebates on PDE and DIR as specified.
    Standalone USG PAP operated by Pfizer: beneficiaries may obtain commercial Paxlovid at $0 cost sharing outside Part D; pharmacies submitting claims to the standalone PAP must not also submit PDEs for those claims, and Part D plans must not coordinate with or seek recoveries from the standalone PAP.
    Plans that exclude commercial Paxlovid from formulary must still process formulary exceptions per 42 CFR §§ 423.566, 423.568, and 423.570 and may not impose prior authorization solely to steer enrollees to the standalone USG PAP operated by Pfizer.
    Reporting and PDE handling: CMS will reject PDEs for EUA-labeled Paxlovid with dates of service after March 8, 2024; sponsors must report PDEs for USG-distributed supply as previously guided while USG-distributed supply remains available; when claims are for USG-distributed supply there will be no ingredient cost and no beneficiary cost sharing (USG vs commercial supply distinguishable via NDCs).
    Timing note: EUA oral antivirals are treated as Part D drugs through December 31, 2024; CMS will address formulary and bid reviews for CY2025 thereafter.

    Medicare beneficiary coverage pathways for commercial oral antivirals

    Primary coverage pathways and responsibilities for Medicare beneficiaries seeking commercial Paxlovid or Lagevrio:

    Determine whether the beneficiary is enrolled in a Medicare Part D plan.
    If enrolled: Beneficiary may obtain the oral antiviral through their Part D plan; cost sharing is determined by the plan benefit design (formulary tier or formulary exception tier and stage in benefit).
    If not enrolled (Paxlovid): Beneficiary may enroll in the standalone USG PAP operated by Pfizer to obtain Paxlovid at $0 cost sharing via a participating pharmacy or via overnight shipping; if the beneficiary cannot locate a participating pharmacy and cannot wait for shipping, they must pay full cost or seek Part D coverage by enrolling in a plan.
    If not enrolled (Lagevrio): Beneficiary may apply to Merck's patient assistance program; program is generally for the uninsured though insured individuals may qualify under special hardship criteria.

    Coding, NDCs, and Reporting

    NDC distinctions for USG-distributed vs commercial suppliesNDC
    0069-0345-30USG-distributed Paxlovid (EUA-labeled) - Carton
    0069-1085-30USG-distributed Paxlovid (EUA-labeled) - Carton
    0069-1101-20USG-distributed Paxlovid (EUA-labeled) - Carton
    0069-1085-06USG-distributed Paxlovid (EUA-labeled) - Blister
    0069-0345-06USG-distributed Paxlovid (EUA-labeled) - Blister
    0069-1101-04Commercial Paxlovid (NDA-labeled)
    0069-5321-30Commercial Paxlovid - Carton
    0069-5317-20Commercial Paxlovid - Carton
    0069-5321-03Commercial Paxlovid - Blister
    0069-5317-02Commercial Paxlovid - Blister
    1–10 of 12
    1/2
    Coverage classificationmixed
    EUA oral antivirals for COVID-19 meet the definition of a Part D drug until December 31, 2024 and must be covered by Part D plans either as a formulary product or through the formulary exception process consistent with 42 CFR § 423.578(b).
    inv-05: PDE ERPOSA reporting requirement
    PDE fieldEstimated Remuneration at Point-of-Sale Amount (PDE field 40 / ERPOSA)
    Reporting requirementWhen a Part D sponsor participates in the USG PAP for Paxlovid, ERPOSA must equal 100% of the negotiated price so that the PDE-reported ingredient cost, dispensing fee, additional dispensing fee, vaccine administration fee, and sales tax are all zero.
    PurposeEnsures beneficiary receives Paxlovid with no out-of-pocket cost or progression through the Part D benefit as a result of the claim.
    CMS enforcement discretionIf additional time is needed to make system changes, CMS will exercise enforcement discretion for the 30-day PDE submission timeframe for Paxlovid dates of service Nov 1, 2023–Dec 31, 2024.
    Related actionPDE records reflecting these rebates must be submitted per the PDE submission process as described by CMS.

    Utilization Management, Determinations, and Prior Authorization

    Prior Authorization

    Utilization management expectations

    Part D sponsors may apply utilization management (UM) edits for oral antivirals but should favor soft-reject edits that can be resolved at point-of-sale; UM requirements that cannot be resolved at point-of-sale should be weighed against the need to initiate treatment quickly. CMS prefers that sponsors leverage technology to implement soft reject edits and will not approve UM criteria that are overly restrictive or inconsistent with the product label (these UM edits requiring CMS approval will be reviewed per Chapter 6 § 30.2.2.1 of the Prescription Drug Benefit Manual).

    • Soft-reject edits are preferred and must be resolvable at point-of-sale.
    • UM criteria that require CMS submission will be reviewed and may be denied if overly restrictive or inconsistent with labeling.
    Denial Risk

    Coverage determination timeframes

    Part D sponsors must process coverage determinations as expeditiously as the enrollee's health condition requires and must use expedited timeframes when delay could seriously jeopardize life, health, or ability to regain maximum function; standard decisions are due within 72 hours and expedited initial coverage determinations within 24 hours. Expedited timeframes apply to formulary exceptions and requests to waive UM requirements.

    Key Definitions

    inv-11: USG-distributed supply
    DefinitionUSG-distributed supply refers to oral antivirals procured and distributed by the U.S. Government (Federal Retail Pharmacy Therapeutics Program or other federal entities).
    LabelingUSG-distributed products may carry EUA labeling while commercial products may be NDA- or EUA-labeled.
    NDCsUSG-distributed products have distinct NDCs from commercial products enabling identification on claims.
    Ordering limitsAfter Nov 10, 2023 (Lagevrio) and Dec 15, 2023 (Paxlovid) most pharmacies could no longer order USG-distributed supply, though supply remained in circulation.
    inv-06: Commercial supply
    DefinitionCommercial supply refers to products sold in the commercial market under distinct NDCs (may be NDA- or EUA-labeled).
    Policy Summary
    Payerglobalhealth
    PolicyIntroduction of Prescription Oral Antivirals for COVID-19 to the Commercial Market
    Policy CodePolicy N/A
    Change TypeModified guidance expanding prior memorandum for commercial transition
    Effective DateFeb 20, 2024
    Next Review DateN/A
    Key ActionPart D sponsors must process expedited coverage determinations when delay could jeopardize beneficiary health.
    SourceLink
    On This Page
    Coverage and Beneficiary PathwaysCoding, NDCs, and ReportingUtilization Management, Determinations, and Prior AuthorizationKey Definitions
    If the beneficiary's Part D plan has contracted with Pfizer to facilitate the USG PAP and Paxlovid is on the formulary via that arrangement, the beneficiary's cost sharing is $0; if the plan has not contracted with Pfizer and excludes Paxlovid, the enrollee may either enroll in the standalone USG PAP or pursue coverage through their Part D plan (including formulary exception requests).
    Operational constraints: Part D plans that exclude commercial Paxlovid must still process formulary exceptions in accordance with 42 CFR requirements and may not impose PA solely to steer beneficiaries to the PAP; pharmacies cannot retroactively bill the standalone USG PAP for claims already adjudicated through Part D.
    CMS encourages Part D sponsors to educate enrollees and network pharmacies about plan participation with Pfizer and may communicate participation via Medicare Plan Finder.
    inv-06: Part D drug designation end date
    Designation end dateEUA oral antivirals are treated as Part D drugs through December 31, 2024.
    Statutory basisPursuant to section 4131 of the Consolidated Appropriations Act, 2023 (CAA, 2023).
    Operational implicationPart D coverage rules (formulary or formulary exception) apply to EUA oral antivirals until 12/31/2024.
    • Standard coverage determinations: decision within 72 hours (42 CFR § 423.568).
    • Expedited initial coverage determinations: decision within 24 hours (42 CFR § 423.570).
    • Expedited processing required if standard timeframe risks delaying therapy to the point the drugs are no longer indicated.
    Prior Authorization

    Formulary exception and prior authorization rules

    Part D plans may not impose prior authorization solely to steer enrollees to the standalone USG PAP operated by Pfizer and must process formulary exceptions in accordance with 42 CFR §§ 423.566, 423.568, and 423.570; plans may use message-only alerts or soft rejects to inform pharmacists about the standalone PAP as long as pharmacists can override them.

    • Plans that exclude commercial Paxlovid must still process formulary exceptions per 42 CFR timeframes and procedures.
    • Plans may not impose PA requirements for the sole purpose of directing enrollees to the standalone USG PAP.
    • Pharmacies cannot retroactively bill the standalone USG PAP if drug was dispensed through Part D and later the enrollee learns the plan was not contracted with Pfizer.
    Documentation Required

    Part D coverage requirement for EUA antivirals

    EUA oral antivirals for COVID-19 meet the definition of a Part D drug through December 31, 2024 and therefore must be covered by Part D plans either on the formulary or via the formulary exception process consistent with 42 CFR § 423.578(b).

    • CMS encourages adding at least one oral antiviral to CY2024 formularies on a preferred or $0 cost-sharing tier where available.
    • If a sponsor contracts with Pfizer to facilitate the USG PAP, commercial Paxlovid must be added to the formulary without prior authorization or step therapy (quantity limits for one full course permitted) and in-network/qualifying out-of-network claims processed at $0 cost sharing for Nov 1, 2023–Dec 31, 2024.
    Paxlovid labelingCommercial Paxlovid will be the FDA-approved, NDA-labeled product.
    Lagevrio labelingCommercial Lagevrio remains EUA-labeled and has a distinct NDC from USG-distributed Lagevrio.
    Claim identificationDistinct commercial NDCs enable plans and processors to identify which supply (USG-distributed vs commercial) was dispensed.
    inv-13: standalone USG PAP
    DefinitionStandalone USG PAP refers to the patient assistance pathway operated by Pfizer that provides commercial Paxlovid to Medicare beneficiaries at $0 cost sharing outside the Part D benefit.
    Plan interactionPart D plans that do not contract with Pfizer may direct enrollees to the standalone USG PAP but must still process formulary exceptions and cannot impose PA solely to steer enrollees to the PAP.
    Coordination prohibitionPart D sponsors cannot coordinate with, seek recoveries from, or allow pharmacies to retroactively bill the standalone USG PAP for claims already submitted to Part D.
    inv-14: EUA oral antivirals
    DesignationEUA oral antivirals for COVID-19 are considered Part D drugs through December 31, 2024.
    Coverage requirementThey must be covered by Part D plans either on the formulary or via the formulary exception process consistent with 42 CFR § 423.578(b).
    Scope noteThis Part D drug designation applies only until 12/31/2024 per section 4131 of the CAA, 2023.